REGENXBIO Inc.
Last updated September 27, 2026
Organization details
- Legal name
- REGENXBIO Inc.
- Former names
- ReGenX Biosciences, LLC
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- Rockville
- Headquarters state / province
- Maryland
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RGNX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001590877
- EIN
- 47-1851754
Board of directors
-
Alexandra Glucksmann · DirectorSince 2023
-
Allan M. Fox · DirectorSince 2023
-
Argeris N. Karabelas · DirectorSince 2023
-
Curran Simpson · Director · Chief Executive OfficerSince 2024
-
Daniel Tasse · DirectorSince 2023
-
David C. Stump · DirectorSince 2023
-
George Migausky V · DirectorSince 2023
-
Gregory Austin Ciongoli · DirectorSince 2026
-
Jean Bennett · DirectorSince 2023
-
Jennifer Zachary · DirectorSince 2023
-
Kenneth T. Mills · Director · President and CEOSince 2023
Chief executives
Kenneth T. Mills
· President and CEO
Dates unknown
Curran Simpson
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 29, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
68.1%
-
90.9%
Board connections
5 of this board's directors also sit on 7 other boards.
- via Gregory Austin Ciongoli
- via Daniel Tasse
- via Gregory Austin Ciongoli
- via George Migausky V
- via David C. Stump
- via Jean Bennett
- via Gregory Austin Ciongoli
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $949,381
- 2 purchases by 1 insider
- Sold, last 12 months
- $1,279,074
- 7 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Mitchell Chan Officer (Chief Financial Officer) | Shares withheld for tax | −4,902 | $9.32 | $45,687 |
| Sep 1, 2026 | Malzahn Craig Officer (Chief Technology Officer) | Shares withheld for tax | −234 | $9.32 | $2,181 |
| Aug 27, 2026 | Gregory Austin Ciongoli Director | Open-market purchase | +53,407 | $9.36 | $499,676 |
| Aug 26, 2026 | Gregory Austin Ciongoli Director | Open-market purchase | +49,196 | $9.14 | $449,706 |
| Aug 25, 2026 | Gregory Austin Ciongoli Director | Grant or award | +15,432 | — | — |
| Aug 1, 2026 | Christmas Patrick J. Officer (Chief Strategy & Legal Officer) | Shares withheld for tax | −4,699 | $9.69 | $45,533 |
| Aug 1, 2026 | PAKOLA STEVE Officer (Chief Medical Officer) | Shares withheld for tax | −7,468 | $9.69 | $72,365 |
| Jul 2, 2026 | PAKOLA STEVE Officer (Chief Medical Officer) | Option exercise | +2,161 | $7.86 | $16,985 |
| Jul 2, 2026 | PAKOLA STEVE Officer (Chief Medical Officer) | Open-market sale | −2,161 | $13.64 | $29,476 |
| Jul 1, 2026 | PAKOLA STEVE Officer (Chief Medical Officer) | Option exercise | +36,725 | $7.86 | $288,659 |
| Jul 1, 2026 | PAKOLA STEVE Officer (Chief Medical Officer) | Open-market sale | −36,725 | $12.86 | $472,284 |
| Jul 1, 2026 | Curran Simpson Director, Officer (Chief Executive Officer) | Shares withheld for tax | −6,818 | $13.09 | $89,248 |
| Jun 30, 2026 | Curran Simpson Director, Officer (Chief Executive Officer) | Grant or award | +1,453 | $10.18 | $14,792 |
| Jun 29, 2026 | PAKOLA STEVE Officer (Chief Medical Officer) | Open-market sale | −19,608 | $11.04 | $216,472 |
| May 29, 2026 | Daniel Tasse Director | Grant or award | +9,807 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.